Methods of treating kidney conditions using modified forms of trimetazidine
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11883396-B2
Publication Date
2024-01-30
Expiration Date
Abstract
The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.
Core Innovation
The invention relates to using a composition comprising a compound of formula (X), or a pharmaceutically acceptable salt thereof, to increase ATP production in a kidney of a subject having a kidney condition. The described approach is focused on kidney conditions and the renal cell energetic state, specifically targeting ATP production within the kidney.
The patent describes a mechanistic basis for the increased ATP production associated with CV-8972 (compound of formula (X)). It describes metabolism in which CV-8972 is initially hydrolyzed to CV-8814 and nicotinic acid, and it links the resulting biochemical effects to increased renal mitochondrial respiration and ATP production.
The document further links these effects to treatment of kidney conditions, including acute kidney injury, acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic nephropathy, diabetic kidney, kidney inflammation, and reperfusion injury. It also describes boosting mitochondrial respiration and ATP production through a NAD+ precursor mechanism and through inhibition of fatty-acid oxidation via the 3-ketoacyl-CoA thiolase pathway.
Claims Coverage
Two independent claims are directed to increasing ATP production in a kidney and treating a kidney condition, each by providing a composition comprising a compound of formula (X) or a pharmaceutically acceptable salt thereof. The coverage centers on the compound-of-formula composition and its use in kidney conditions.
Increasing ATP production in a kidney using a compound of formula (X) composition
A method of increasing ATP production in a kidney of a subject by providing to a subject having a kidney condition a composition comprising a compound of formula (X) or a pharmaceutically acceptable salt thereof.
Treating a kidney condition using a compound of formula (X) composition
A method of treating a kidney condition in a subject by providing to a subject having a kidney condition a composition comprising a compound of formula (X) or a pharmaceutically acceptable salt thereof.
Oral provision of the composition
Providing the composition orally.
Modified-release formulation or immediate-release formulation
Providing the composition as a modified-release formulation or as an immediate-release formulation.
Selected kidney condition from an enumerated list
Selecting the kidney condition from a specified list of various renal diseases and related conditions including acute kidney injury, acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic nephropathy, diabetic kidney, kidney inflammation, reperfusion injury, glomerular and tubular disorders, kidney stones and obstructions, and transplant-related or systemic causes of renal dysfunction.
Quantified daily dose range
Providing a daily dose containing about 25 mg to about 1000 mg of the compound of formula (X).
Administration frequency constraint
Providing the composition in one daily dose or providing the composition in multiple daily doses per day.
Across the two independent claims, the main inventive coverage is providing a composition comprising a compound of formula (X), or a pharmaceutically acceptable salt thereof, to a subject having a kidney condition to increase ATP production in the kidney or to treat the kidney condition. The dependent claims then narrow coverage by specifying oral administration, formulation type, selection of kidney condition from an enumerated list, quantitative daily-dose range, and administration frequency.
Stated Advantages
Increase ATP production in a kidney of a subject having a kidney condition.
Treat a kidney condition in a subject.
Documented Applications
Treatment of kidney conditions including acute kidney injury (AKI), acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic nephropathy/diabetic kidney, kidney inflammation, and reperfusion injury.
Use in a clinical evidence context including a Phase 1 first-in-human study for IMB-1018972/trimetazidine, with safety and tolerability and pharmacokinetics described in the partial content.
Interested in licensing this patent?